Meeting Banner
Abstract #2653

Metabolic Imaging Biomarker kio Discriminates Breast Tumor Therapy Time-Courses

Wei Huang1,2, Alina Tudorica3, Karen Y. Oh3, Stephen Y-C. Chui2,4, Nicole Roy3, Megan L. Troxell2,5, Arpana Naik2,6, Kathleen A. Kemmer4, Yiyi Chen2,7, Megan L. Holtorf2, Aneela Afzal1, Xin Li1, and Charles S. Springer, Jr.1

1Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR, United States, 2Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States, 3Diagnostic Radiology, Oregon Health & Science University, Portland, OR, United States, 4Medical Oncology, Oregon Health & Science University, Portland, OR, United States, 5Pathology, Oregon Health & Science University, Portland, OR, United States, 6Surgical Oncology, Oregon Health & Science University, Portland, OR, United States, 7Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, United States

The new DCE-MRI biomarker kio measures on-going vital metabolic activity. For subjects with biopsy-proven breast IDC, it monitors the course of neoadjuvant therapy. While kio decreases for most tumors, for a sub-set it increases during therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here